GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Interest Expense
Switch to:

Biogen (MEX:BIIB) Interest Expense

: MXN-4,724 Mil (TTM As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biogen's interest expense for the three months ended in Mar. 2023 was MXN -1,127 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2023 was MXN-4,724 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biogen's Operating Income for the three months ended in Mar. 2023 was MXN 9,324 Mil. Biogen's Interest Expense for the three months ended in Mar. 2023 was MXN -1,127 Mil. Biogen's Interest Coverage for the quarter that ended in Mar. 2023 was 8.28. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Biogen Interest Expense Historical Data

The historical data trend for Biogen's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Interest Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,938.78 -3,534.36 -4,425.97 -5,202.35 -4,807.71

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Interest Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,316.12 -1,323.76 -1,204.89 -1,068.38 -1,126.56

Biogen Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4,724 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biogen's Interest Expense for the three months ended in Mar. 2023 was MXN-1,127 Mil. Its Operating Income for the three months ended in Mar. 2023 was MXN9,324 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2023 was MXN119,140 Mil.

Biogen's Interest Coverage for the quarter that ended in Mar. 2023 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2023 )/Interest Expense (Q: Mar. 2023 )
=-1*9324.332/-1126.562
=8.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines